Dr. Kuykendall on the Evaluation of Momelotinib in Myelofibrosis
Andrew Kuykendall, MD, discusses the evaluation of momelotinib in patients with symptomatic and anemic myelofibrosis.
Dr. Kuykendall on Treatment Considerations with Ruxolitinib in Myelofibrosis
Andrew Kuykendall, MD, discusses treatment considerations with ruxolitinib in myelofibrosis.
Dr. Kuykendall on Prognostication Factors in Myelofibrosis
Andrew Kuykendall, MD, discusses the evolution of prognostication factors in primary and secondary myelofibrosis.
PD-1 Inhibitor Combinations, Alternative Therapeutic Approaches Are Moving the Needle in NSCLC
Better Understanding of Biomarkers Can Inform Immunotherapy Treatment in SCLC
Second-Line Treatment of R/R LBCL With Lisocabtagene Maraleucel (Liso-cel)
ZUMA-7: Axicabtagene Ciloleucel as a Second-Line Therapy for LBCL
2 Clarke Drive Cranbury, NJ 08512